Mitochondrial Dysfunction in Alzheimer’s Disease and Mitochondria-Targeted Therapeutics
Open Access
Abstract
Alzheimer’s disease (AD) is the most prevalent form of dementia and is characterized by progressive cognitive decline due to the loss of neurons. The accumulation of extracellular senile plaques (Aβ) and intracellular tau neurofibrillary tangles (NFTs) is a key pathological feature of AD. Mitochondrial dysfunction is implicated in all key AD pathologies, whether as a cause or a consequence of disease progression. Growing evidence indicates that mitochondrial impairment plays a central role in AD pathogenesis by disrupting cellular homeostasis, promoting oxidative stress, and contributing to progressive neuronal death. Therefore, targeting mitochondria may offer promising insights into the development of disease-modifying therapies. In this review, we summarize current evidence on the role of mitochondrial dysfunction in the pathophysiology of AD and on its therapeutic potential.Keywords
Funding Information
- National Institutes of Health (R01 AG071560)
This publication has 166 references indexed in Scilit:
- Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functionsAlzheimer's & Dementia, 2024
- Gene therapy for mitochondrial disordersJournal of Inherited Metabolic Disease, 2024
- The role of mitochondrial dysfunction in Alzheimer's disease pathogenesisAlzheimer's & Dementia, 2022
- Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer’s diseaseActa Neuropathologica, 2018
- Mitochondrial biogenesis in neurodegenerationJournal of Neuroscience Research, 2017
- A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's diseaseMovement Disorders, 2010
- Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR‐A radiationIUBMB Life, 2010
- Potential in vivo amelioration by N‐acetyl‐L‐cysteine of oxidative stress in brain in human double mutant APP/PS‐1 knock‐in mice: Toward therapeutic modulation of mild cognitive impairmentJournal of Neuroscience Research, 2010
- PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of DementiaArchives of Neurology, 2009
- FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009